Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Reinhard, Ruckser"'
Autor:
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Niklas Zojer, Laurenz Schöffmann, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Reinhard Ruckser, Boris Bozic, Maria‐Theresa Krauth, Andreas Petzer, Clemens Schmitt, Sigrid Machherndl‐Spandl, Hermine Agis, Michael Fillitz, Song‐Yau Wang, Stefan Knop, Richard Greil
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 494-504 (2024)
Abstract Understanding the impact of induction and maintenance therapy on patients’ quality of life (QoL) is important for treatment selection. This study aims to compare patient‐reported QoL between patients treated with KTd or KRd induction the
Externí odkaz:
https://doaj.org/article/024099f3e64d40079ea0f35121c1b82f
Autor:
Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Christoph Tinchon, Niklas Zojer, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Woell, Reinhard Ruckser, Boris Bozic, Maria Theresa Krauth, Andreas Petzer, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Michael Fillitz, Song-Yau Wang, Stefan Knop, Bruno Paiva, Richard Greil
Publikováno v:
HemaSphere, Vol 7, p e55498d5 (2023)
Externí odkaz:
https://doaj.org/article/6331fd869261467da7450cd271583f31
Autor:
Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, Niklas Zojer, Johannes Andel, Bernd L. Hartmann, Christoph Tinchon, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Martin Schreder, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Hermine Agis, Michael Fillitz, Song-Yau Wang, Stefan Knop, Sarah Kainz, Bruno Paiva, Richard Greil
Publikováno v:
Blood. 140:10185-10188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d778432b877c5d50d5785c4b507b04e
https://doi.org/10.1182/blood-2022-162336
https://doi.org/10.1182/blood-2022-162336
Publikováno v:
Wiener Medizinische Wochenschrift. 173:216-220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e32f0af83e11734d7bce1109f64fc757
https://doi.org/10.1007/s10354-022-00975-6
https://doi.org/10.1007/s10354-022-00975-6
Autor:
Philipp B. Staber, Berend Snijder, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Niklas Zojer, Christoph C. Zielinski, Dominik Wolf, Cora Waldstein, Stefan Vogt, Katrina Vanura, Emiel van der Kouwe, Peter Valent, Renate Thalhammer, Ismet Srndic, Wolfgang R. Sperr, Cathrin Skrabs, Christian Sillaber, Edgar Selzer, Ilse Schwarzinger, Ann-Sofie Schmolke, Ana-Iris Schiefer, Julius Salamon, Reinhard Ruckser, Robin Ristl, Markus Raderer, Gerald W. Prager, Edit Porpaczy, Alexander Pichler, Michael Panny, Leopold Öhler, Katharina Ocko, Thomas Noesslinger, Peter Neumeister, Leonhard Müllauer, Katsuhiro Miura, Olaf Merkel, Elisabeth Menschel, Marius E. Mayerhoefer, Simone Lubowitzki, Trang Le, Stefan Kubicek, Gerhard Krajnik, Nikolaus Krall, Barbara Kiesewetter, Lukas Kenner, Lukas Kazianka, Ulrich Jaeger, Georg Hopfinger, Mir Alireza Hoda, Daniel Heintel, Tim Heinemann, Alexander W. Hauswirth, Bernd Lorenz Hartmann, Marcus Hacker, Wolfgang Gstöttner, Hildegard T. Greinix, Klaus Geissler, Alexander Gaiger, Maurizio Forte, Verena Felsleitner-Hauer, Ruth Exner, Harald Esterbauer, Martin Erl, Ruth Eichner, Sandra Eder, Michael Bergmann, Günther Bayer, Gregory I. Vladimer, Tea Pemovska, Christoph Kornauth
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9887042c05486a909c745cd96689d6c
https://doi.org/10.1158/2159-8290.c.6549464.v1
https://doi.org/10.1158/2159-8290.c.6549464.v1
Autor:
Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, Ismet Srndic
Publikováno v:
Cancer Discovery, 12 (2)
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ef6465faab2cb5917a550f8e3d5a11
https://doi.org/10.1158/2159-8290.cd-21-0538
https://doi.org/10.1158/2159-8290.cd-21-0538
Autor:
Wolfgang Schimetta, Ernst Forjan, Reinhard Ruckser, Maria Theresa Krauth, Juergen Thiele, Heinz Gisslinger, Dominik Wolf, Bettina Gisslinger, Sonja Heibl, Veronika Buxhofer-Ausch, Siegfried Sormann
Publikováno v:
European Journal of Haematology
Objectives Cell counts have a significant impact on the complex mechanism of thrombosis in patients with essential thrombocythemia (ET). We recently demonstrated a considerable impact of white blood cell (WBC) counts on thrombotic risk in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b12fa3e029d9c74b77fad16ced02dce4
https://doi.org/10.1111/ejh.13516
https://doi.org/10.1111/ejh.13516
Publikováno v:
Wiener medizinische Wochenschrift (1946)Literatur.
Being one of the most common tumor entities worldwide, the colorectal carcinoma accounts for approximately 10% of all tumor-related deaths. With screening programs such as preventive colonoscopy, a decreasing incidence and mortality rate can be seen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::90d7475e8dce51cdecea4c216355c3b0
https://pubmed.ncbi.nlm.nih.gov/36348129
https://pubmed.ncbi.nlm.nih.gov/36348129
Autor:
Krysztina Racz, Martin Kocher, Reinhard Ruckser, Jens Rutner, Christian Sebesta, Georg Tatzreiter, Boris Bozic, Chang Zheng, Flonza Selimi
Publikováno v:
Cancers, Vol 13, Iss 5036, p 5036 (2021)
Cancers
Cancers
Simple Summary The treatment of patients with relapsed/refractory multiple myeloma has advanced considerably in recent years, irrespective of whether they are younger or older patients. Treating patients with relapsed/refractory multiple myeloma and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f55d608a303950478ef2c6069e2c00
https://www.mdpi.com/2072-6694/13/20/5036
https://www.mdpi.com/2072-6694/13/20/5036
Autor:
Michael Fillitz, Reinhard Ruckser, Richard Greil, Alexander Egle, Boris Bozic, Bernd L. Hartmann, Clemens A. Schmitt, Maria-Theresa Krauth, Siegfried Sormann, Johannes Andel, Heinz Ludwig, Ewald Wöll, Andreas L. Petzer, Sigrid Machherndl-Spandl, Eberhard Gunsilius, Hermine Agis, Axel Hinke, Martin Schreder, Niklas Zojer, Wolfgang Willenbacher, Christoph Tinchon, Thomas Melchardt, Klaus Podar
Publikováno v:
Blood. 136:27-29
Introduction Carfilzomib-based induction therapy is highly effective in newly diagnosed pts with multiple myeloma (NDMM), but information on quality of life (QoL) during first line and maintenance therapy is not available. Here, we analyze patient-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7b2f039cc9fed3b1fd808f4ded67d80
https://doi.org/10.1182/blood-2020-140701
https://doi.org/10.1182/blood-2020-140701